The Company has incurred operating losses and negative cash flows from operations since inception. As of July 30th, DBV's available cash and cash equivalents are not projected to be sufficient to support the Company's operating plan for at least the next 12 months. As such, there is substantial doubt regarding its ability to continue as a going concern. The Company intends to seek additional capital as it continues research and development efforts and prepares for the launch of Viaskin Peanut, if approved. ...

DBV Technologies S.A. (Registrant) | --- | --- | --- | |-------|----------------------------------------------------------------------------------------------------------|-------| | By: | /s/ Daniel Tassé | | | | Daniel Tassé | | | | Chief Executive Of icer (Principal Executive Of icer) | | | By: | /s/ Virginie Boucinha | | | | Virginie Boucinha Chief Financial Of icer (Principal Financial and Accounting Of icer) | | Date: July 30, 2024 24 See "Note 2: Significant Events and Transactions – Legal Proceedings ...

DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 Interested participants may access this call via the below teleconferencing numbers and asking to join the DBV Technologies call: A live webcast of the call will be available on the Investors & Media section of the Company's website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV's website after the event. DBV Technologies is a clinical-stage ...

Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions with significant unmet medical needs [4] - The company is headquartered in Châtillon, France, with North American operations in Warren, NJ [2] - DBV's ordinary shares are traded on Euronext Paris and its American Depositary Shares (ADSs) are traded on the Nasdaq Global Select Market [2] Technology and Products - DBV Technologies is investigating the use of its proprietary technology platform, Viaskin, to address food allergies through epicutaneous immunotherapy (EPIT™) [4] - The Viaskin platform aims to introduce microgram amounts of biologically active compounds to the immune system via intact skin, seeking to modify the underlying allergy by re-educating the immune system [4] - The company is currently conducting clinical trials for Viaskin Peanut in peanut allergic toddlers and children [4] Upcoming Events - DBV Technologies will host a conference call and live audio webcast on July 30, 2024, at 5:30 p.m. ET to review its second quarter 2024 financial results and provide a business update [1][7] - A live webcast of the call will be available on the company's website, with a replay accessible after the event [6]

Media Contact Angela Marcucci DBV Technologies angela.marcucci@dbv-technologies.com AMF Regulated Information Montrouge, France, July 8, 2024 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appea ...

AMF Regulated Information Montrouge, France, July 8, 2024 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of June 30, 2024: 303,744 DBV Technologies shares, € ...

Châtillon, France, June 5, 2024 DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Stock Market (Ticker: DBVT). A replay will also be available on DBV Technologies' website for 90 days after the event. About DBV Technologies DBV Technologies is a clin ...

(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024 Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights Total gross of voting rights: 96,493,078 05/31/2024 96,493,078 Total net* of voting rights: 96,236,383 * Net total = total number of voting rights attached to shares – shares without voting rights Att ...

Châtillon, France, May 30, 2024 DBV Technologies to Participate in Upcoming EAACI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced its upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress May 31 – June 3 in Valencia, Spain. A flash talk pres ...

Core Viewpoint - DBV Technologies is actively participating in the EAACI 2024 Congress to present its research on Viaskin Peanut, focusing on its potential to treat peanut allergies in young children and the importance of understanding accidental peanut consumption during treatment [1][2][3]. Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company dedicated to developing treatment options for food allergies and other immunologic conditions, particularly through its proprietary Viaskin technology [7]. - The company aims to address significant unmet medical needs in food allergies, which affect millions, including young children [7]. Upcoming Events - DBV Technologies will present a flash talk on data from its EPITOPE Phase 3 study regarding accidental peanut consumption in toddlers aged 1 to 3 years during the EAACI Congress [2][5]. - The company will host a symposium titled "Epicutaneous Route: An Innovative Potential Approach to Food Immunotherapy," featuring expert lectures on the clinical applications of epicutaneous immunotherapy [3][6]. Research Focus - The company emphasizes the importance of establishing long-term safety and clinical data for Viaskin Peanut, particularly in pediatric populations, to understand the implications of accidental allergen exposure [3]. - DBV Technologies is conducting ongoing clinical trials for Viaskin Peanut in peanut-allergic toddlers and children, aiming to modify the immune response to allergens through epicutaneous immunotherapy [7]. Exhibition Details - DBV will have an exhibit booth (F10) at the EAACI Congress, where attendees can learn more about its ongoing clinical trials and the Viaskin technology [4].